Posted 29th April 2019 by Joshua Broomfield
Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.
Posted 26th April 2019 by Joshua Broomfield
Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.
Posted 24th April 2019 by Joshua Broomfield
Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.
Posted 17th April 2019 by Joshua Broomfield
David Snead is Consultant Histopathologist and Clinical lead for Coventry and Warwickshire Pathology Services (CWPS), a network of labs hosted by University Hospitals of Coventry and Warwickshire NHS Trust. As head of the UHCW Digital Pathology Centre of Excellence, he is now heavily involved in the Pathology image data Lake for Analytics, Knowledge, and Education (PathLAKE).
Posted 15th April 2019 by Joshua Broomfield
Merck, Sharp & Dohme operates a hub model with IT hubs in the US, Czech Republic, and Singapore.
All operations and important functions of IT are distributed within those three hubs. It ensures not only that we follow the standard model but also ensures the regional presence and cooperation with the sites in any region.
Posted 12th April 2019 by Joshua Broomfield
A key feature of our Congresses is the opportunity given to early career researchers to present their work.
At the upcoming 7th Plant Genomics & Gene Editing Congress: Europe, Egem Ozbudak will be one of four early career researchers to be given a 15-minute platform to present their work and receive a free registration pass for both days of the conference.
He will be discussing his research project on Colletotrichum acutatum, the causative agent of anthracnose crown and fruit rot, recognized as the second most important pathogen of strawberries on the globe due to its economic impacts.
Posted 10th April 2019 by Joshua Broomfield
Technology is constantly changing the healthcare industry. Scientists and physicians are hard at work doing everything they can to enhance treatment options for patients battling many different types of diseases and cancers. Immuno-oncology (I-O) is a subarea of immunotherapy that is uncovering new ways that cancer can be treated. This type of treatment allows patients to participate in less invasive and taxing procedures all while finding newer treatment options on a more niche or case by case level. Immunotherapy treatments and supporting procedures are making their way into everyday cancer care to change the playing field for the better.
Posted 8th April 2019 by Joshua Broomfield
The human gut is a complex ecosystem dominated by bacteria and their viruses, i.e. phages. Approximately half of the viruses that reside in our intestine are derived from lysogens, bacteria that contain normally dormant viruses – prophages — in their genome.